Small Cell Lung Cancer
Conditions
Interventions
None listed
Sponsors
Kyoto Prefectural University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Aged 18 years or older at the time of consent with a performance status of 0-3. Recurrent small-cell lung cancer, regardless of the number of prior treatment lines. At least one evaluable lesion according to RECIST version 1.1. Scheduled to receive tarlatamab therapy. Patients who have received a thorough explanation of this clinical study and have provided written informed consent voluntarily.
Exclusion criteria
Exclusion criteria: Patients deemed inappropriate by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate, progression-free survival, time to treatment failure, overall survival, and safety of tarlatamab therapy; improvement in performance status Efficacy and safety of tarlatamab therapy for central nervous system lesions Association between the efficacy and safety of tarlatamab therapy and patient characteristics Association between the efficacy and safety of tarlatamab therapy and cancer cachexia Association between the efficacy and safety of tarlatamab therapy and the treatment line Association between the efficacy and safety of tarlatamab therapy and eligibility for clinical trial criteria Association of the efficacy and safety of tarlatamab therapy with gut microbiota composition and diversity, as well as tumor immune microenvironment factors | — |
Countries
Japan
Contacts
Public ContactHayato Kawachi
Kyoto Prefectural University of Medicine Department of Graduate School of Medicine, Respiratory Medicine,
Outcome results
None listed